Analysts predict that Omeros Co. (NASDAQ:OMER) will report sales of $28.80 million for the current quarter, according to Zacks. Two analysts have made estimates for Omeros’ earnings, with the highest sales estimate coming in at $32.70 million and the lowest estimate coming in at $24.90 million. Omeros reported sales of $4.61 million in the same quarter last year, which indicates a positive year-over-year growth rate of 524.7%. The company is scheduled to issue its next earnings report on Thursday, November 14th.
On average, analysts expect that Omeros will report full year sales of $111.15 million for the current fiscal year, with estimates ranging from $99.90 million to $122.40 million. For the next financial year, analysts anticipate that the company will post sales of $158.60 million, with estimates ranging from $102.50 million to $214.70 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Omeros.
Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.15. The business had revenue of $26.80 million during the quarter, compared to the consensus estimate of $25.33 million. During the same period last year, the business posted ($0.70) EPS. The firm’s revenue for the quarter was up 1476.5% compared to the same quarter last year.
In related news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $15.12, for a total transaction of $75,600.00. Following the transaction, the director now owns 35,067 shares of the company’s stock, valued at approximately $530,213.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.80% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ingalls & Snyder LLC lifted its stake in Omeros by 1.2% in the third quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock valued at $82,038,000 after buying an additional 58,198 shares in the last quarter. BlackRock Inc. lifted its stake in Omeros by 1.1% in the second quarter. BlackRock Inc. now owns 3,858,463 shares of the biopharmaceutical company’s stock valued at $60,539,000 after buying an additional 40,412 shares in the last quarter. Vanguard Group Inc. lifted its stake in Omeros by 1.2% in the second quarter. Vanguard Group Inc. now owns 2,401,494 shares of the biopharmaceutical company’s stock valued at $37,679,000 after buying an additional 28,991 shares in the last quarter. Northern Trust Corp lifted its stake in Omeros by 0.9% in the second quarter. Northern Trust Corp now owns 636,210 shares of the biopharmaceutical company’s stock valued at $9,982,000 after buying an additional 5,642 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Omeros by 1.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 268,719 shares of the biopharmaceutical company’s stock valued at $4,217,000 after buying an additional 3,725 shares in the last quarter. 53.13% of the stock is currently owned by hedge funds and other institutional investors.
Omeros stock traded up $0.46 during midday trading on Friday, hitting $15.86. 371,286 shares of the stock were exchanged, compared to its average volume of 344,380. The company has a fifty day simple moving average of $17.19 and a two-hundred day simple moving average of $17.35. Omeros has a 52 week low of $10.30 and a 52 week high of $20.92. The stock has a market capitalization of $759.03 million, a PE ratio of -7.14 and a beta of 2.84.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: What is the definition of arbitrage?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.